Patients on GLP-1 medications (semaglutide, tirzepatide) who are losing weight but want to preserve lean muscle mass and improve body composition rather than just losing weight and shrinking
Reported Adverse Events in Trial Data Across the retatrutide trial program, gastrointestinal adverse events nausea, vomiting, and diarrhea were the most frequently reported, consistent with the broader GLP-1 receptor agonist class [3][4]
Another study found that L-carnitine supplementation improved running performance in runners by 8%
176 While each potential agent is beyond the scope of this review, we will focus on selected compounds anticipated for phase 3 trials, grouped by their mechanism of action and detailed in Table 4
He focuses on building strong leadership pipelines, building engaged teams, and connecting talent development to business success